Table 2.

Baseline and 12-month follow-up urinary aMT6s geometric means (ng/mg creatinine), overall and within subgroups

Baseline12-mo Follow-up
ExercisersControlsExercisersControls
Mean (95%CI)Mean (95%CI)Mean (95%CI)Change (%)Mean (95%CI)Change (%)Pa
Overall6.0 (4.8–7.6)6.7 (5.3–8.3)6.4 (5.2–7.9)0.4 (6.5)7.5 (6.2–9.2)0.9 (13.1)0.66
(n = 95)(n = 100)(n = 95)(n = 99)
Age, y
 <557.2 (5.4–9.7)6.4 (4.7–8.7)6.7 (5.0–9.0)−0.5 (−7.1)8.0 (6.1–10.4)1.6 (24.8)0.18
(n = 46)(n = 54)(n = 46)(n = 53)
 ≥555.1 (3.6–7.1)7.0 (5.0–9.7)6.1 (4.6–8.3)1.1 (20.6)7.0 (5.2–9.5)0.1 (0.7)0.29
(n = 49)(n = 46)(n = 49)(n = 46)
Sex
 Men4.9 (3.7–6.6)5.4 (4.0–7.3)5.2 (3.9–7.0)0.3 (6.7)5.7 (4.3–7.6)0.3 (5.8)1.00
(n = 49)(n = 51)(n = 49)(n = 50)
 Women7.5 (5.3–10.6)8.3 (6.0–11.5)7.9 (5.9–10.6)0.4 (5.7)10.0 (7.8–12.8)1.7 (20.4)0.55
(n = 46)(n = 49)(n = 46)(n = 49)
BMI, kg/m2
 <257.2 (4.5–11.4)4.6 (2.6–8.2)7.2 (4.3–12.0)−0.0 (−0.3)7.7 (5.0–11.9)3.1 (67.1)0.17
(n = 23)(n = 19)(n = 23)(n = 19)
 25–294.7 (3.3–6.6)6.1 (4.1–9.0)5.2 (3.9–7.0)0.6 (12.0)6.9 (4.7–10.1)0.8 (13.4)0.96
(n = 32)(n = 37)(n = 32)(n = 37)
 ≥306.7 (4.6–9.8)8.5 (6.4–11.3)7.1 (5.1–9.8)0.4 (5.7)8.1 (6.3–10.4)−0.4 (−4.6)0.59
(n = 40)(n = 44)(n = 40)(n = 43)
  • aP value comparing the changes from baseline to follow-up between exercisers and controls.